Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [CPT-R10-58-11] to Ferritin Light Chain
- Suitable for: ELISA
- Reacts with: Human
Product nameAnti-Ferritin Light Chain antibody [CPT-R10-58-11]
See all Ferritin Light Chain primary antibodies
Species reactivityReacts with: Human
Synthetic peptide within Human Ferritin Light Chain aa 150 to the C-terminus. The exact sequence is proprietary.
Database link: P02792
- ELISA: CPTAC-14d peptide.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.03% EDTA, 0.59% Sodium citrate
Concentration information loading...
PurityProtein A purified
|ELISA||Use a concentration of 0.01 - 4 µg/ml.|
FunctionStores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney.
Involvement in diseaseDefects in FTL are the cause of hereditary hyperferritinemia-cataract syndrome (HHCS) [MIM:600886]. It is an autosomal dominant disease characterized by early-onset bilateral cataract. Affected patients have elevated level of circulating ferritin. HHCS is caused by mutations in the iron responsive element (IRE) of the FTL gene.
Defects in FTL are the cause of neurodegeneration with brain iron accumulation type 3 (NBIA3) [MIM:606159]; also known as adult-onset basal ganglia disease. It is a movement disorder with heterogeneous presentations starting in the fourth to sixth decade. It is characterized by a variety of neurological signs including parkinsonism, ataxia, corticospinal signs, mild nonprogressive cognitive deficit and episodic psychosis. It is linked with decreased serum ferritin levels.
Sequence similaritiesBelongs to the ferritin family.
Contains 1 ferritin-like diiron domain.
- Information by UniProt
- Ferritin L chain antibody
- Ferritin L subunit antibody
- Ferritin light chain antibody
100 ng CPTAC-14d (2000 ng/mL, 50 μL per well) was coated onto 96-wells. Serial dilutions (0, 0.01, 0.02, 0.05, 0.15, 0.44, 1.33, 4.00 μg/mL) of ab241329 (50 μL) were incubated with CPTAC-14d in each well for 60 minutes by shaking. This was followed by adding goat anti-rabbit IgG, (H+L), phosphatase-conjugated secondary antibody (50 μL) into each well and incubating for another 40 minutes. After washing, 50 μL of PNPP was added and incubated for 15 minutes without shaking for color development. OD was read at 405 nm within 5 minutes.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab241329 has not yet been referenced specifically in any publications.